AVDL vs PGNY vs JAZZ vs HIMS vs SUPN

For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.

8% revenue growth year-over-year, versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). Progyny, Inc. (PGNY) offers the better valuation at 36. 5x trailing P/E (20. 0x forward), making it the more compelling value choice. Analysts rate Avadel Pharmaceuticals plc (AVDL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Progyny, Inc.

(PGNY) is the cheapest at 36. 5x versus Hims & Hers Health, Inc. at 55. 4x. On forward P/E, Jazz Pharmaceuticals plc is actually cheaper at 9. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -53. 4% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: SUPN returned +223. 7% versus PGNY's +48. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.

19β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 1222% more volatile than AVDL relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.

8% versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). On earnings-per-share growth, the picture is similar: Avadel Pharmaceuticals plc grew EPS 74. 5% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -28. 9% for Avadel Pharmaceuticals plc — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus -25. 1% for AVDL. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Jazz Pharmaceuticals plc (JAZZ) trades at 9.

1x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 49. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 29. 8% to $30. 80.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Avadel Pharmaceuticals plc (AVDL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), +113. 0% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVDL: +113. 0%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AVDL is a small-cap high-growth stock; PGNY is a small-cap quality compounder stock; JAZZ is a mid-cap quality compounder stock; HIMS is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.